1 / 19

Topical, Oral; Daily, Intermittent; Single, Combination agents;

Topical, Oral; Daily, Intermittent; Single, Combination agents;. What do we need AND what will work? Patrick Ndase, Microbicide Trials Network & Dep’t of Global Health, University of Washington. THE BOLD STATEMENT.

Télécharger la présentation

Topical, Oral; Daily, Intermittent; Single, Combination agents;

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Topical, Oral;Daily, Intermittent;Single, Combination agents; What do we need AND what will work? Patrick Ndase, Microbicide Trials Network & Dep’t of Global Health, University of Washington

  2. THE BOLD STATEMENT Within the research & advocacy community, there is a lot of enthusiasm & hope around the promise of ARV-based approach to HIV prevention • Biomedical piece that will likely revolutionalize HIV prevention

  3. WE NEED • Topical AND Oral ARV-based intervention • Know your HIV status = Know your options • Daily dosing as a 1st step but Intermittent dosing based on exposure times preferred • Single agents if efficacious & out of treatment realm desired, but the search for combination agents ought to continue

  4. Key stakeholders’ question has been……. • How can you explain the enthusiasm around ARV based prevention, amidst ever diminishing slots for people in desperate need of care? • Shall funders have the much needed momentum for prevention in light of failed sustained momentum for treatment? • Can’t the biomedical prevention approach be mismanaged?

  5. Reminder of why we need additional prevention tools now • For every 2 people started on ART in Southern Africa, • 3 become newly infected • In South Africa alone • >1500 new HIV infections are Estimated to occur daily • An approx 70,000 babies are born with HIV annually • Bottom line: • We need to prevent new infections if we’re to effectively • treat those who need care. http://www.avert.org/aidssouthafrica.htm

  6. The Face of HIV in Uganda • 110,000 new infections every year (> 300 new infections everyday) • 73,000 (66%) of new infections annually are women. • 47% of the women living with advanced have no access to anti-retroviral therapy • 52% percent access PMTCT (21% of new infections due to MTCT)

  7. The New York Times on Uganda At Front Lines, AIDS War Is Falling Apart • ~ 500,000 need • treatment • 200,000 getting • treatment • Each year approx • an additional • 110,000 infected

  8. HIV slots not only limited to Uganda • Economy Hurts Government Aid for H.I.V. Drugs, New York Times of June 30th, 2010 • FORT LAUDERDALE, Fla. Nearly 1,800 have been relegated to rapidly expanding • waiting lists that less than three years ago had dwindled to zero. http://www.nytimes.com/2010/07/01/us/01aidsdrugs.html?hp

  9. Proving the skeptics wrong • ART roll-out in resource limited settings will never be possible • Countries now constrained with stock-outs & few slots for new entrants • Adherence to ART will be poor in the developing world • Some of highest reported adherence rates • Resistance a major worry due to programmatic failure (NOT poor adherence)

  10. Signal of willingness to access prevention services • Documented HIV Prevalence on Island is 17% [2006 Sentinel survey] • Having sex is single most important risk factor in context of high prevalence • Up to 5hrs en-route study clinic for PrEP • Participants wake up 3:00AM to start journey • Yet with excellent retention

  11. Topical, Oral;Daily, Intermittent;Single, Combination agents; What do we need AND what will work?

  12. HSV-2 Treatment - Infectiousness Index Partner Treatment Microbicide - BufferGel, PRO2000 CAPRISA 004 TDF Gel Microbicide - Dapivirine gel & ring Oral TDF & Truvada & Tenofovir gel - VOICE Microbicide - PRO2000 Oral TDF -MSM US (Ph II) Oral Truvada - MSM (iPrEx) Oral TDF, Truvada - Partners PrEP Oral Truvada – Heterosexual Botswana Oral Truvada - FemPrEP Oral TDF - IDU Thailand Is the field poised to provide all we need? KEY Testing & linkage to care plus (TLC+) Treatment as PX Vaccines Microbicides Vaccine - Prime/Boost Thailand Vaccine - DNA Prime/Ad5 Boost US New Vaccine concept(s) PrEP TMC 278 - UK (Ph I/II) 2011+ 2010 2015+ 2009

  13. What will be lacking? The three issues here all point to efficacy; QUESTION: But how much of an impact does efficacy have on the epidemic?

  14. The Prvention Cascade – 50% Access/Adherence 100 Women Exposed to HIV (10% transmission risk) Access to Microbicides/ PrEP 50% 50 have access 50 have no access TOTAL 25 use Use Microbicides/ PrEP50% 75 do not use No Product − 10 infections 1.3 infections 7.5 infections If 50% − 9 infections Product50%effective 0.5 infections 7.5 infections Product80%effective If 80% − 8 infections

  15. The Microbicide/PrEP Cascade – 95% Access/Adherence 100 Women Exposed to HIV (10% transmission risk) Access to Microbicides/ PrEP 95% 95 have access 5 have no access TOTAL 90 use Use Microbicides/ PrEP95% 10 do not use No Product – 10 infections If 50% − 6 infections 4.5 infections 1 infection Product50%effective 1.8 infections 1 infection Product80%effective If 80% − 3 infections

  16. The prevention Cascade The effectiveness of an intervention, matters but coverage matters even more

  17. Impact of ARV-based prevention on epidemic Modeling work (Imperial College London) • Targeting most at-risk populations • Extent of coverage of these populations • Adherence/Acceptability of the interventions

  18. An old challenge!Can we deliver on the promise? Estimates of Coverage Unmet Need for HIV Prevention HIV testing 5% 20% 39% 80% Condom Use 15% 85% 9% Male Circumcision 10% 75% 25% Antiretrovirals for PMTCT 9% 32% 45% 55% Contraception for PMTCT 85% 14% 15% 0% 40% 60% 80% 100% 20% 2006/7 2004 Unmet HIV Prevention Need 2008 Sources: UNAIDS, 2004; UNGASS, 2008; WHO, 2009

  19. Thank You The Microbicide Trials Network The International Clinical Research Center at UW

More Related